Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 43

recruiting
3 987
countries
28
conditions
2 109

690 trials match your criteria

Study on the Effects of Pariglasgene Brecaparvovec for Adults with Glycogen Storage Disease Type Ia

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pariglasgene Brecaparvovec

Asthma

Not recruiting

Study on the Effectiveness and Safety of AZD4604 for Adults with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA

Investigational
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:(2R)-N-[3-(5-Fluoro-2-{[2-Fluoro-3-(Methylsulfonyl)Phenyl]Amino}-4-Pyrimidinyl)-1H-Indol-7-Yl]-3-Methoxy-2-(4-Methyl-1-Piperazinyl)Propanamide-1-Hydroxy-2-Naphthoic Acid

Study Comparing Radium-223 Dichloride with Abiraterone Acetate, Enzalutamide, and Prednisone in Patients with Advanced Prostate Cancer Spread to the Bone

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate

Study on JTT-861 for Patients with Heart Failure with Reduced Ejection Fraction

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:JTT-861 monohydrochloride dihydrate

Plasma cell myeloma

Not recruiting

Study Comparing Talquetamab, Pomalidomide, and Teclistamab for Patients with Relapsed or Refractory Myeloma After 1 to 4 Prior Treatments

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib

Study on Durvalumab with Oleclumab or Monalizumab for Patients with Stage III Unresectable Non-Small Cell Lung Cancer After Chemoradiation Therapy

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab

Asthma

Not recruiting

Study on Long-Term Safety of Depemokimab for Adults and Adolescents with Severe Eosinophilic Asthma

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Depemokimab

Breast cancer+3

Not recruiting

Study of Capivasertib and Fulvestrant for Patients with Advanced or Metastatic HR+/HER2- Breast Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Capivasertib

Study on the Effects of RGX-314 Gene Therapy Compared to Aflibercept and Ranibizumab for Patients with Neovascular Age-Related Macular Degeneration

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept

Study on Elinzanetant for Treating Hot Flashes in Women with or at High Risk for Hormone-Receptor Positive Breast Cancer

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Elinzanetant

Bladder cancer

Not recruiting

Study of Sacituzumab Govitecan, Zimberelimab, and Domvanalimab for Patients with Muscle Invasive Bladder Cancer Ineligible for Cisplatin Chemotherapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Domvanalimab

Study on the Effectiveness of Autogene Cevumeran in Patients with ctDNA Positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Autogene Cevumeran
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.